


Axinn Protects Client Endo Pharmaceuticals Inc.'s Approval for Generic Valcyte[®]

NEWS | LESS THAN 1 MIN READ

March 11, 2015

Axinn, on behalf of client Endo Pharmaceuticals Inc., successfully defended the U.S. Food and Drug Administration's final approval of Endo's generic Valcyte[®] by securing summary judgment in favor of Endo and FDA. Plaintiff Ranbaxy Laboratories, Ltd. had sought an order reversing FDA's approval of Endo's generic Valcyte[®] product after FDA recently decided to revoke tentative approval of Ranbaxy's generic Valcyte[®] ANDA and determined that Ranbaxy had forfeited its generic marketing exclusivity rights. Judge Beryl Howell of the United States District Court for the District of Columbia determined that FDA had acted within its authority.

Related People



Thomas K. Hedemann

To subscribe to our publications, [click here](#).

Featured Insights

- GCR Live: Law Leaders Europe 2025
SPEAKING ENGAGEMENT ANTITRUST
- AHLA Annual Meeting 2025
SPEAKING ENGAGEMENT ANTITRUST
- SABA North America Annual Conference 2025
SPEAKING ENGAGEMENT ANTITRUST
- Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses
WEBINAR ANTITRUST
- NJSBA Annual Meeting and Convention 2025
SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY
- Cost-Effective and Efficient IP Litigation Strategies – Making Paragraph IV Litigation Work for You
WEBINAR INTELLECTUAL PROPERTY
- Hartford HealthCare Black and Red Gala 2025
SPONSORSHIP ANTITRUST
- Informa CompLaw Antitrust West Coast Conference 2025
SPEAKING ENGAGEMENT ANTITRUST
- AHLA Health Care Transactions Program 2025
SPONSORSHIP ANTITRUST
- Axinn Welcomes Former DOJ Antitrust Lawyer in DC
MEDIA MENTIONS ANTITRUST

